Australian (ASX) Stock Market Forum

CSL - CSL Limited

Jump to new
it's all downhill from here... ⤵

Screenshot_20240131-124830_CommSec~2.jpg
 
Brokers reckon there are two key things to look out for when CSL releases its results next Tuesday .

The first is its profit growth and whether it is on course to achieve its guidance in FY 2024. Morgans is expecting a solid first half performance. It said:

FY24 guidance suggests solid 1H. FY24 constant currency guidance calls for NPATA US$2.9-3bn (13-17%) on 9-11% revenue growth, with operating efficiency improving, B/S leverage declining (2x ND/EBITDA) and ROIC "steadily improving" over time.
Click to expand...
Elsehwere, the team at Citi is forecasting 17.6% earnings per share growth in FY 2024. So, its analysts will no doubt be looking for similar growth during the first half.

Another metric to keep an eye on is the gross margin of the key CSL Behring business. This arguably has the biggest impact on the company's profitability. So, if this margin shows signs of improvement, it could go down well with the market.

According to a note out of UBS, the consensus estimate for CSL Behring's gross margin is 50.3%. This is slightly ahead of the broker's estimate of 49.8%.

Citi, Morgans, and UBS are all bullish on CSL and currently have the equivalent of buy ratings on its shares.

Citi has a buy rating and $325 price target, Morgans has an add rating and $328.20 price target, and UBS has a buy rating and price target of $350.
 
CSL received the top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-[human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction. The study did not meet its primary efficacy endpoint of MACE reduction at 90 days.

As a result, there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112.
.
and down 6 per cent
Screenshot_20240212-100419_CommSec.jpg
 
Dona Ferentes said:
CSL received the top-line results
from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-[human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).
The study did not meet its primary efficacy endpoint of MACE reduction at 90 days.

As a result,there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112.
Click to expand...
So that should see csr fall a bit .maybe...
As with resmed, I see csl as a USD/AUD play as well so tricky..
 
UMike said:
And just as I was poised to lighten the load a little bit when breaking $305.
Click to expand...
gotta luv the market
UMike said:
Hopefully the results to be released make up for this setback.
Click to expand...
Head of research and development Bill Mezzanotte said in November that CSL112 was one of three potential blockbuster drugs in its development pipeline.
 
The issue with research is 95% or more of it results in a dead-end and they have to do the research in order to prove it is a dead-end. However, it is always possible some elements of that research may be useful in other research projects.
 
Belli said:
The issue with research is 95% or more of it results in a dead-end and they have to do the research in order to prove it is a dead-end. However, it is always possible some elements of that research may be useful in other research projects.
Click to expand...

The government also provides a significant tax incentive to conduct R&D on Australian shores/balance sheets

Research and development tax incentive | Australian Taxation Office

Apply for the research and development (R&D) tax offset for income years commencing on or after 1 July 2021.
www.ato.gov.au www.ato.gov.au
 

CSL tumbles as key heart attack drug fails trial, why the market is so disappointed​


www.livewiremarkets.com

CSL tumbles as key heart attack drug fails trial, why the market is so disappointed

Just because CSL hadn’t factored in financial benefit from CSL112, it doesn’t mean the market hadn’t.
www.livewiremarkets.com www.livewiremarkets.com

i do not hold this share

and am not so disappointed the big slide rippled onto AUI ( CSL was the top holding ) causing me to get a satisfactory entry point ( for AUI )

i suppose i should have doubled down and looked for a bashed ETF as well
 
FINANCIAL HIGHLIGHTS
• Revenue $8.05 billion, up 11% at CC
• NPAT $1.90 billion, up 17%
• NPAT $1.94 billion at CC, up 20%
• NPATA $2.02 billion , up 11%
• NPATA $2.06 billion at CC, up 13%
• NPATA earnings per share $4.182, up 11%
• NPATA earnings per share $4.26 at CC up 13%
• Interim dividend of US$1.19 per share
o Converted to Australian currency, the interim dividend is approximately A$1.81 per share, up 12%
• Guidance reaffirmed – FY24 NPATA anticipated to be in the range of approximately $2.9 billion to $3.0 billion at CC

... things are looking UP
 
yes

nice work to those who bravely bought the dip yesterday

will be interesting to see if any members admit to trading CSL over the next week or two ( say bought yesterday and exit around $320 )
 
UMike said:
My thinking is anywhere near $320 I'll lighten the load.
Click to expand...
i note CSL is currently in the red , which is a surprise to me

the numbers didn't look bad at all ( even if you inflation adjust )

and the unsuccessful drug trial happened early enough to allow a diversion of capital if that is what management deem prudent

but yes a shareholder with a high entry-point would be tempted
 

Similar threads

GamestopVALUE
GME - GameStop Corp (NYSE)
2
Replies
20
Views
3K
GamestopVALUE
GamestopVALUE
Dona Ferentes
The role of Private Equity
Replies
4
Views
1K
qldfrog
qldfrog
Ferret
ASX Index Tracking ETFs
Replies
19
Views
2K
Bellcose
B
Garpal Gumnut
Thoughts on Trading and Investing : Garpal Gumnut :
Replies
15
Views
2K
Garpal Gumnut
Garpal Gumnut
R
Best Swing Trading Strategy
Replies
0
Views
2K
robertbanking
R
Top